Clinical Trials Logo
  1. Home
  2. Pancreatic Neuroendocrine Tumors
  3. NCT01648465

Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors Clinical Trial

Official title:
Phase II Multicenter Single-arm Study Evaluating the Safety and Efficacy of Everolimus as a First-line Treatment in Newly-diagnosed Patients With Advanced GI Neuroendocrine Tumors.

Clinical Trial Summary

The purpose of this study is to explore the efficacy and safety of everolimus administered as a first-line treatment in newly-diagnosed patients with advanced or inoperable Gastrointestinal (GI) or pancreatic neuroendocrine tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01648465
Study type Interventional
Source Hellenic Cooperative Oncology Group
Contact
Status Terminated
Phase Phase 2
Start date August 6, 2012
Completion date August 6, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03053999 - Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Completed NCT02586844 - Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
Terminated NCT00947167 - A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors Phase 2
Completed NCT02842749 - Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Phase 4
Unknown status NCT01381822 - Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors Phase 1
Completed NCT01384617 - Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy N/A
Completed NCT02841865 - Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Completed NCT01121562 - Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT02685553 - Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project Phase 1
Completed NCT02282059 - The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Terminated NCT02110563 - Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Phase 1
Completed NCT02125929 - Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms N/A